Merck & Co. has reached an agreement to supply Molnupiravir to the U.S. government. The COVID-19 drug is now in Phase 3 trials. If it is approved by the FDA, the U.S. government will purchase the drug for 1.7 million courses of treatment, valued at $1.2 billion.
Merck & Co. has reached an agreement to supply Molnupiravir to the U.S. government. The COVID-19 drug is now in Phase 3 trials. If it is approved by the FDA, the U.S. government will purchase the drug for 1.7 million courses of treatment, valued at $1.2 billion. 
merck.com
English (US) 